Am J Surg Pathol

1. FADARE O, Fard EV, Bhargava R, Desouki MM, et al
   The Malignant Potential of Ovarian Steroid Cell Tumors Revisited: A Multi-institutional Clinicopathologic Analysis of 115 Cases.
   Am J Surg Pathol. 2024 Mar 21. doi: 10.1097/PAS.0000000000002201.
   

   >> Share

   
   
2. RUIZ F, Tjendra Y, Millan N, Gomez-Fernandez C, et al
   Trichorhinophalangeal Syndrome Type 1 Immunohistochemical Expression in Carcinomas of Gynecologic Origin.
   Am J Surg Pathol. 2024 Feb 15. doi: 10.1097/PAS.0000000000002193.
   

   >> Share

   
   

   
   BMC Cancer

3. DE OLIVEIRA FERREIRA C, Carneiro VCG, Araujo Mariz C
   Germline mutations in BRCA1 and BRCA2 among Brazilian women with ovarian cancer treated in the Public Health System.
   BMC Cancer. 2024;24:499.
   

   >> Share

   
   

   
   Br J Cancer

4. KMENT J, Newsted D, Young S, Vermeulen MC, et al
   Blockade of TGF-beta and PD-L1 by bintrafusp alfa promotes survival in preclinical ovarian cancer models by promoting T effector and NK cell responses.
   Br J Cancer. 2024 Apr 15. doi: 10.1038/s41416-024-02677.
   

   >> Share

   
   
5. MONJE N, Dragomir MP, Sinn BV, Hoffmann I, et al
   AHRR and SFRP2 in primary versus recurrent high-grade serous ovarian carcinoma and their prognostic implication.
   Br J Cancer. 2024 Feb 9. doi: 10.1038/s41416-023-02550.
   

   >> Share

   
   

   
   Cancer Res

6. WATERS JA, Robinson M, Lujano-Olazaba O, Lucht C, et al
   Omental preadipocytes stimulate matrix remodeling and IGF signaling to support ovarian cancer metastasis.
   Cancer Res. 2024 Apr 18. doi: 10.1158/0008-5472.CAN-23-2613.
   

   >> Share

   
   

   
   Clin Cancer Res

7. VENEZIANI AC, Sneha S, Oza AM
   Antibody-Drug Conjugates: Advancing from Magic Bullet to Biological Missile.
   Clin Cancer Res. 2024;30:1434-1437.
   

   >> Share

   
   
8. GITTO SB, Whicker M, Davies G, Kumar S, et al
   A B7-H4-Targeting Antibody-Drug Conjugate Shows Antitumor Activity in PARPi and Platinum-Resistant Cancers with B7-H4 Expression.
   Clin Cancer Res. 2024;30:1567-1581.
   

   >> Share

   
   

   
   Eur J Obstet Gynecol Reprod Biol

9. GUZEL D, Terek C, Besler A, Serin G, et al
   PURE vs. mixed clear cell ovarian carcinomas: Is there any impact on survival?
   Eur J Obstet Gynecol Reprod Biol. 2024;296:321-326.
   

   >> Share

   
   
10. GUO L, Kang X, Su Y, Liu X, et al
    Oncologic and reproductive outcomes after fertility-sparing surgery for bilateral borderline ovarian tumors: A retrospective study.
    Eur J Obstet Gynecol Reprod Biol. 2024;296:107-113.
    

    >> Share

    
    

    
    Gynecol Oncol

11. EHMANN S, Lam C, Zhou Q, Iasonos A, et al
    Secondary cytoreductive surgery and oncologic outcomes in the era of targeted maintenance therapy for recurrent, platinum-sensitive ovarian cancer.
    Gynecol Oncol. 2024;186:104-109.
    

    >> Share

    
    

    
    PLoS One

12. LI N, Jin S, Wu J, Ji H, et al
    Effect of different treatment modalities on ovarian cancer patients with liver metastases: A retrospective cohort study based on SEER.
    PLoS One. 2024;19:e0299504.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share